
Zydus Lifesciences announced receiving approval from the USFDA to market generic Gabapentin tablets in 300 mg and 600 mg strengths for managing postherpetic neuralgia. Being the first company to gain final approval for these tablets, Zydus plans an immediate launch in the US market. The product, with annual US sales of USD 85 million according to IQVIA data, aims to address the therapeutic need. Despite the news, Zydus shares experienced a 2.27% decline, trading at Rs 735.30 apiece on the BSE.
Like
Save
Share